Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aktis Oncology, Inc. (AKTS)
Boston, MA, US
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.01% | +3.88% | +12.63% | +9.97% | -12.81% | -12.81% | -12.81% | -12.81% | -12.81% | -12.81% | -12.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
30.00
+22.2%
|
| Last Year | 2 |
30.50
+24.3%
|
| All Time | 2 |
30.50
+24.3%
|
-
Revenue growth Biotechnology: +1.6%+336.9% ★
-
EPS growth Biotechnology: +29.7%+5.6%
-
FCF margin FCF growth · Biotechnology: +16.2%-1,199.3% Q1'26: -808.7%
-
EBIT margin Biotechnology: +0.0%-1,149.5% Q1'26: -703.6%
-
ROIC Biotechnology: -16.1%— Q1'26: +436.7%
-
Share dilution Biotechnology: -3.4%+50.7%
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.13×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
100.0K
est.
|
600.0K
est.
|
1.37M
est.
|
1.43M
est.
|
1.85M
est.
|
6.97M
est.
|
—
est: 16.31M (-100.0%)
|
—
est: 28.82M (-100.0%)
|
1.49M
est: 40.00M (-96.3%)
|
6.50M
est: 7.27M (-10.6%)
|
18.29M
9.80M – 35.60M
+151.6% YoY
|
17.72M
6.41M – 37.40M
-3.1% YoY
|
3.00M
1.30M – 6.13M
-83.1% YoY
|
3.00M
1.30M – 6.13M
+0.0% YoY
|
130.50M
56.37M – 266.83M
+4,250.0% YoY
|
| EBITDA |
-100.0K
est.
|
-600.0K
est.
|
-1.37M
est.
|
-18.77M
est.
|
-1.85M
est.
|
-27.65M
est.
|
-19.32M
est: -37.79M (+48.9%)
|
-33.60M
|
-50.48M
|
-72.36M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-100.0K
est.
|
-600.0K
est.
|
-1.37M
est.
|
-20.33M
est.
|
-1.85M
est.
|
-29.72M
est.
|
-19.76M
est: -43.19M (+54.2%)
|
-34.79M
|
-52.05M
|
-74.68M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-32.07M
est.
|
-51.22M
est.
|
-90.57M
est.
|
-20.77M
est.
|
-92.95M
est.
|
-32.88M
est.
|
-17.93M
est: -43.19M (+58.5%)
|
-28.64M
est: -37.16M (+22.9%)
|
-43.98M
est: -17.20M (-155.7%)
|
-63.73M
est: -3.85B (+98.3%)
|
-84.65M
-101.92M – -45.63M
+97.8% YoY
|
-127.83M
-159.83M – -63.33M
-51.0% YoY
|
-184.67M
-444.00M – -49.25M
-44.5% YoY
|
-192.49M
-453.91M – -50.35M
-4.2% YoY
|
-161.24M
-380.22M – -42.17M
+16.2% YoY
|
| SGA |
236.9K
est.
|
1.42M
est.
|
3.24M
est.
|
3.40M
est.
|
4.38M
est.
|
16.52M
est.
|
5.11M
est: 14.33M (-64.4%)
|
7.68M
est: 83.18M (-90.8%)
|
11.31M
est: 115.43M (-90.2%)
|
12.60M
est: 20.97M (-39.9%)
|
52.77M
28.27M – 102.72M
+151.6% YoY
|
51.13M
18.50M – 107.93M
-3.1% YoY
|
8.66M
3.74M – 17.70M
-83.1% YoY
|
8.66M
3.74M – 17.70M
+0.0% YoY
|
376.59M
162.67M – 769.99M
+4,250.0% YoY
|
| EPS |
-0.36
est.
|
-0.58
est.
|
-1.02
est.
|
-1.13
est.
|
-1.04
est.
|
-1.12
est.
|
-0.51
est: -1.09 (+53.2%)
|
-0.82
est: -0.71 (-15.9%)
|
-1.26
est: -0.25 (-404.0%)
|
-1.19
est: -55.16 (+97.8%)
|
-1.62
-1.94 – -0.87
+97.1% YoY
|
-2.16
-3.04 – -1.21
-32.9% YoY
|
-3.59
-8.45 – -0.94
-66.1% YoY
|
-3.67
-8.64 – -0.96
-2.2% YoY
|
-3.07
-7.24 – -0.80
+16.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 5.01M | 6.90% | 4.96M | — | 5.01M | — | HC | Delaware | 2024-01-26 | ↗ |
| 2 | Richard Mashaal | 3.80M | 5.30% | — | 3.80M | — | — | HC, IN | Delaware | 2023-09-14 | ↗ |
| 3 | Senvest Management, LLC | 3.80M | 5.30% | — | 3.80M | — | — | IA, OO | Delaware | 2023-09-14 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 3.63M | 5.00% | — | 110.7K | — | 145.2K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 5 | (1)Names of reporting persons. BlackRock, Inc. | 2.97M | 5.70% | 2.94M | — | 2.97M | — | HC | Delaware | 2022-02-04 | ↗ |
| 6 | Mark N. Tompkins | 1.77M | 7.90% | 1.77M | — | 1.77M | — | IN | Canada | 2018-02-15 | ↗ |
| 7 | COLUMBUS CAPITAL MANAGEMENT, LLC | 1.75M | 7.80% | 1.75M | — | 1.75M | — | IA | CALIFORNIA | 2018-04-26 | ↗ |
| 8 | MATTHEW D. OCKNER | 1.75M | 7.80% | 1.75M | — | 1.75M | — | HC, IN | UNITED STATES OF AMERICA | 2018-04-26 | ↗ |
| 9 | Jeffrey B. Shealy | 1.45M | 3.80% | 1.45M | — | 1.45M | — | IN | USA | 2020-10-02 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | God Bless America ETF YALL | 1.75% | 1.77M | 0.65% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.78% | 450.4K | 0.65% |
| 3 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.03% | 91.4K | 0.39% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.03% | 3.83M | 0.24% |
| 5 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.02% | 1.21M | 0.30% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.02% | 580.4K | 0.30% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.02% | 10.7K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.02% | 15.67M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.02% | 102.2K | 0.36% |
| 10 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.02% | 60.1K | 0.25% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | ELI LILLY & Co | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 6,344,114 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Roden | President, CEO & Director | 914.7K | — |
| Akos Czibere | Chief Medical Officer | 676.9K | — |
| Paul L. Feldman | Chief Scientific Officer | 642.4K | — |
| Shulamit Ron-Bigger | Chief Operating Officer | 536.7K | — |
| Kyle D. Kuvalanka | Chief Financial Officer | — | male |
| Carlos Rodriguez | Executive Director of Corporate Development | — | male |
| Patrick A. Baeuerle | Co-Founder & Member of Scientific Advisory Board | — | — |
| Todd Foley | Co-Founder & Chairman | — | male |
| Dasa Lipovsek | VP & Head of Lead Discovery | — | — |
| Tyler Benedum | Chief Technical Officer | — | — |
| Karen McCarthy | VP & Head of Finance | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AKTS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
